The Nancy Owens Breast Cancer Foundation, a local nonprofit dedicated to supporting breast cancer research, provides funding to Houston Methodist Research Institute. As a result, Dr. Alessandro Grattoni and his research group have developed a nanotechnology-based drug delivery approach for application in breast cancer prevention.
The nanochannel drug delivery system achieves sustained delivery of tamoxifen, an FDA-approved drug for estrogen-receptor-positive (ER+) breast cancer, in breast tissue, reducing whole-body exposure to the drug. In pre-clinical trials, the delivery of tamoxifen eliminated the need for multiple injections and lowered the associated side effects of oral tamoxifen.
– Kirby Cohen, The PR Boutique